Diabetes-related eye diseases have attracted enormous attention of the healthcare community at large and primary care providers engaged in classification, diagnosis, and treatment. The global burden of diabetes - economic, social, and health-related - is alarming and continues to grow. It has over the past decades grown unabated in young people and the elderly populations in several developing and developed countries. Key ocular complications include diabetic retinopathy (DR), diabetic cataracts, and dry eye syndrome (DES).
Diabetes mellitus poses high mortality and morbidity due to vascular complications, primarily due to prolonged survival of diabetic patients. Primary care providers have collaborated with ophthalmologists for evaluating and managing diabetes-related risk factors for vision impairment. Several studies have established the role of hyperglycemia in complications of DR.
The growing contribution of diabetes in vision loss and blindness in working-age adults is a key driver for strides in the diabetes associated ophthalmic treatment market. Over the years, the world has witnessed growing burdens of diabetes and DR. The concerns have been growing on the back rise of growing frequency of screening procedures in patients with type 1 and type 2 diabetes.
Per a finding by International Federation of Diabetes (IFD), as many as 642 million people in the world will be living with diabetes in 2040. Together with the rising incidence, the prevalence of DR will also mount to alarming levels, thus imparting an impetus to DR screening programs.
The social and emotional burden of diabetes-induced vision impairment has spurred diabetics to refer to the ophthalmologists who make them aware of the risk factors in the different stages of the disease. This has bolstered the growth of the diabetes associated ophthalmic treatment market. Expectedly, ocular guidelines pertaining to pathophysiology, diagnosis, and treatment of diabetic retinopathy (DR) have also evolved.
DR has been found to be one the leading causes of blindness especially among adults aged 20–74 years. Its advanced form - diabetic macular edema (DME) - poses a considerable burden on the health of the working population. A better understanding of stage of retinopathy and complications in DR patients has stridently changed the course of diabetes associated ophthalmic treatment market over the past few years.
According to a study published in the NCBI, the reported prevalence of DES in diabetics amounts to 15–33% in those over 65 years of age, where the aging is viewed as an accelerating factor. Consequently, examination of the dry eye has grown in clinical significance, thereby enriching the landscape of diabetes associated ophthalmic treatment market. The growing incidence of dry eye syndrome in patients with diabetes mellitus is worrisome. The trend has steered R&D in understanding ocular surface system/lacrimal function. The research continues to guide treatment strategies of diabetes mellitus associated DES. These are central to interventions for diabetes associated ophthalmic treatments.
Researchers have made a huge progress in identifying downstream immune-inflammatory regulators and proteins causing LFU dysfunction. Players have used these findings to develop better strategies for prevention and treatment regimens. Recommendations by the Working Group of Ocular Health has enriched screening procedures of DR. Players in diabetes associated ophthalmic treatment market. are keen on commercializing new technologies in the early diagnosis of DR.
Some of the key players in the diabetes associated ophthalmic treatment market are Pfizer, Inc, Carl Zeiss Meditec, Novartis AG, Bayer AG, and Johnson & Johnson Services, Inc.
The Europe is a promisingly lucrative region in the global market. The growth has been fueled by extensive study made in the prevention and treatment strategies for DR and DME. A lot of efforts have bene led by the European Society of Retina Specialists.
North America diabetes associated ophthalmic treatment market has in recent years witnessed substantial revenue streams, led by massive opportunities in the U.S. Rise in demand for screening procedures in patients with type 1 and type 2 diabetes and standardized DR screening programs have led to the development of the regional market.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Complete the form below and we'll get back to you shortly.